Melanocortin & reproductive
Melanocortin signaling, reproductive endocrinology, fertility, and sexual-health medicines.
Questions
What does the Melanocortin and reproductive category cover?
The sampled monographs span melanocortin agonists bremelanotide, afamelanotide, and unapproved Melanotan II, plus the reproductive-endocrine medicines leuprolide and degarelix. The grouping supports navigation across related signaling systems without implying common indications or interchangeable effects.
How do the sampled melanocortin entries differ in status?
Bremelanotide and afamelanotide have approvals for specific medical indications documented in their monographs. Melanotan II has no approved indication in the reviewed jurisdictions and is associated with regulator warnings about unregulated products. Afamelanotide and Melanotan II are distinct substances.
How do leuprolide and degarelix differ mechanistically?
Leuprolide is a GnRH agonist that initially causes a hormone surge before suppression. Degarelix is a GnRH receptor antagonist and does not cause that initial surge. Both have documented prostate-cancer indications, but their mechanisms and labeled regimens are not interchangeable.
Can evidence for afamelanotide be transferred to Melanotan II?
No. Afamelanotide is a distinct approved drug with a specific erythropoietic protoporphyria indication and controlled clinical evidence. Melanotan II has a different sequence, lacks approval, and is chiefly documented through limited studies and safety warnings. Similar marketing language does not make their evidence transferable.
What should readers verify for reproductive medicines in this category?
Readers should verify the exact active substance, product, indication, and jurisdiction. Leuprolide products have formulation-specific labels, while degarelix has its own defined labeled use. The monographs preserve these distinctions because a category label cannot establish equivalence between agonists, antagonists, or products.
Join the atlas. Get the evidence updates.
Receive concise notes when peptide evidence, status, or source records change.